药品信息、包装与临床用药安全.pptVIP

A Systemic Problem that Harms Patients 药品包装与用药安全 不够突出的提醒和警告 药品包装与用药安全 不够突出的提醒和警告 United States (before) (after) 药品包装与用药安全 色标不安全的应用 药品包装与用药安全 色标不安全的应用 Australia Email to: songqingliu@ * * * * * 现有版本1996年版，收载药名7500个（不含商品名）。中国药品通用名称2010版尚在编撰中。 国食药监注[2006]99号关于进一步规范药品名称管理的通知对药品商品名等进行了规范。 药品商品名称不得有夸大宣传、暗示疗效作用。 药品商品名称的使用范围应严格按照《药品注册管理办法》的规定，除新的化学结构、新的活性成份的药物，以及持有化合物专利的药品外，其他品种一律不得使用商品名称。 钠、钾盐，盐酸盐等 International standards organisations attempt to ensure that the names of different drugs (both generic and trade name) are sufficiently distinct from each other. However, given the huge, everincreasing volume of drugs available, this is a challenging task. For a clinician searching for an unfamiliar or infrequently-used drug, this list is problematic as it contains a large number of similar-looking and sounding names. A list like this increases the possibility of mis-selection, potentially leading to the wrong drug being administered to the patient. When prescribing, confusion and error can occur during selection of drugs which look or sound alike. This concern has been raised by the World Health Organization,which publishes a list of ‘look-alike, soundalike’ drugs. Recent research commissioned by NHS CFH found a 0.33% error rate when selecting a drug product from lists containing ‘look-alike, sound-alike’ names. As there are over 500 million prescriptions written in the UK each year, this would equate to a large number of incorrect scripts per annum. It is therefore important to find ways to ensure that selection of drug names and other attributes is as error-free as possible. Connecting for Health. Final report of the use of TallMan lettering to minimise selection errors of medicine names in computer prescribing and dispensing systems. (2009). Available at: www. connectingforhealth.nhs.uk/systemsandservices/eprescribing/refdocs/tallman.pdf Connecting for Health. Final report of the use of TallMan lettering to minimise selection errors of medicine names in computer prescri